Ganli Pharmaceutical (603087.SH) released its semi-annual performance report, with a net profit of 604 million yuan attributable to the parent company, representing a year-on-year increase of 101.96%.

Zhijian Financial News APP, Ganli Pharmaceutical (603087.SH) released its 2025 interim report, with a revenue of 2.067 billion yuan in the reporting period, a year-on-year increase of 57.18%, and a net profit attributable to shareholders of the listed company of 604 million yuan, a year-on-year increase of 101.96%; non-recurring net profit was 488 million yuan, a year-on-year increase of 284.47%; basic earnings per share were 1.02 yuan.